ASTELLAS-2138-CL-0101
Phase I
OPEN TO ACCRUAL
A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
CHUGAI-SPK101JG
Phase I
OPEN TO ACCRUAL
A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors
HCRN-GI18-333-SEQUEL
Phase II
OPEN TO ACCRUAL
Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) with Anti-Angiogenesis and Chemotherapy in Advanced Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
HOFFMANN-BO41932-TAPISTRY
Phase II
OPEN TO ACCRUAL
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
INHIBRX-PH1-INBRX-106
Phase I/II
OPEN TO ACCRUAL *
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
MABSPACE-TST001-1001
Phase I/II
OPEN TO ACCRUAL
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination with Nivolumab or Standard of Care in Patients with Locally Advanced or Metastatic Solid Tumors
MAYO-18-1612-BIOREPOSITORY
Phase N/A
OPEN TO ACCRUAL
Exploration of tumor biology in patients with metastatic esophageal and gastric cancer (biorepository protocol for prospective tissue collection)
MERCK-MK1084-001
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRAS G12C Mutant Advanced Solid Tumors
MIRATI-1719-001
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
TECLISON-LT-004-TATE-PD1
Phase II
OPEN TO ACCRUAL
Phase IIA Single-Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody
WON-UW19029
Phase II
OPEN TO ACCRUAL
Phase 2 Trial of 5-Fluorouracil, Oxaliplatin, Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-Positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma